MYCN and neuroblastoma: The possibilities of neuroblastoma therapeutics based on targeting of MYCN have advanced recently, notably with the demonstration that small molecule inhibitors targeting Aurora kinase A such as Alisertib (MLN8237) can trigger depletion of MYCN protein in NB cell‐lines and in the murine model of NB, leading to NB growth inhibition and tumour regression.